Gilead Aims to Showcase its Legacy in HIV Research at AIDS 2024
Significant Progress in HIV Prevention, Treatment, and Cure Programs
Gilead will present new data from its comprehensive research and collaborations designed to combat the HIV epidemic.
Late-Breaking Full Results from PURPOSE 1 Trial
The full results from the PURPOSE 1 trial, which evaluates lenacapavir, a twice-yearly injectable medication for HIV prevention. PURPOSE 1 is notable for being the first HIV prevention trial to intentionally include pregnant and lactating women. In June, interim analysis results showed 100% efficacy for lenacapavir in preventing HIV among cisgender women.
Oral Presentation on ARTISTRY-1
The latest 48-week data from the ARTISTRY-1 trial, a Phase 2/3 study (NCT05502341), will be shared. This study evaluates an investigational once-daily single-tablet regimen that combines bictegravir and lenacapavir in virologically suppressed individuals with HIV on complex treatment regimens.
Two-Year Outcomes from BICSTaR
New findings from the BICSTaR study, a global observational study, will be presented. This study examines the effectiveness, safety, and tolerability of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in both treatment-naïve and treatment-experienced individuals with HIV who have significant comorbidities. Additional studies will highlight five-year outcomes of Biktarvy as a long-term treatment for older adults and the Hispanic/Latine community with high comorbidity burdens.
New Data on GS-1720 and GS-4182
Gilead will present findings on GS-1720 and GS-4182, two investigational agents being explored as potential once-weekly oral HIV treatments. Additionally, resistance analyses from a study evaluating a combination of lenacapavir, teropavimab (GS-5423, TAB), and zinlirvimab (GS-2872, ZAB) will be shared, supporting previous data on this novel, long-acting, twice-yearly treatment option.
Focus on Innovative HIV Research
Gilead's presentations at AIDS 2024 will feature data and insights from their HIV prevention, treatment, and cure programs. These studies and trials highlight Gilead’s latest efforts in developing effective HIV therapies and prevention strategies.
ViiV Targets Biktarvy Market with Dovato Two-Drug Regimen Demonstrating Non-Inferiority
ViiV Healthcare has its sights set on the Biktarvy market, presenting data that shows its two-drug regimen, Dovato (dolutegravir/lamivudine), is non-inferior to the three-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
In a significant head-to-head randomized clinical trial, the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study compared the efficacy, safety, and weight changes experienced by participants on Dovato versus those on Biktarvy. The results, to be presented at the 25th International AIDS Conference in Munich, Germany, highlight the potential of Dovato as an effective alternative for virologically suppressed adults looking to optimize their treatment.
Key Findings
Efficacy and Safety: The 48-week study demonstrated that Dovato maintains viral suppression effectively, showing non-inferiority to Biktarvy.
Weight Changes: The trial also assessed weight gain among participants, providing a comprehensive view of the treatment's impact.
Additional Research
DYAD Study: This study focused on virologically suppressed participants with no prior virologic failure, comparing those who switched to Dovato with those who remained on Biktarvy over 48 weeks.
SOUND Study: A 96-week analysis of participants with an unknown resistance history who transitioned from Biktarvy to Dovato.
Broader Pipeline and Real-World Data
ViiV Healthcare will also present findings on other innovative treatments at the conference:
Apretude (Cabotegravir Long-Acting for PrEP): Pregnancy data from the HPTN 084 open-label extension study, focusing on maternal, pregnancy, and infant safety outcomes.
Third-Generation Integrase Inhibitor (VH184): Phase I data on this new integrase strand transfer inhibitor, showcasing its potent activity against resistant mutations.
CAB+RPV LA (Cabotegravir + Rilpivirine Long-Acting): Real-world evidence from multiple studies, including patient perspectives, adherence, and effectiveness.
Comments